ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
GlaxoSmithKline and Cold Spring Harbor Laboratory will jointly develop a treatment for obesity and type 2 diabetes using an approach discovered at Cold Spring to regulate the enzymatic activity of the protein tyrosine phosphatase 1B. The partners hope to identify small molecules that inhibit PTP1B after stimulation by insulin and leptin, an approach expected to overcome the insulin and leptin resistance encountered in diabetes and obesity. Separately, GSK is open for submissions to the third annual Discovery Fast Track Challenge, in which the company solicits drug discovery proposals from academic scientists in Europe, Canada, and the U.S. Those whose entries are selected will work with GSK’s researchers to test their hypotheses against GSK’s extensive library of compounds.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter